Our research indicated that by detecting the levels of ATF4, GPX4, GSS, KEAP1, and ATG3 in the peripheral blood of patients with ovarian cancer, their progression and prognosis could be rapidly, accurately, and effectively predicted, and their sensitivity to adjuvant therapy with ferroptosis-related drugs could be predicted. Here, GPX4 is linked to ovarian carcinoma.